Is PHA 738144 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use PHA 738144? Is PHA 738144 safe for nursing mother and child? Does PHA 738144 extracts into breast milk? Does PHA 738144 has any long term or short term side effects on infants? Can PHA 738144 influence milk supply or can PHA 738144 decrease milk supply in lactating mothers?

Monoclonal antibody directed against TNF (tumoral necrosis factor) that is used for treatment of autoimmune diseases like Rheumatoid Arthritis and Crohn's Disease. Probably because of a high molecular weight, no detectable traces have been found in mother's milk. It is not absorbed by the gut which is even more protective for the nursing infant. No harm effect has been shown among breastfed infants whose mothers were treated with this medication. Avoid using it in the two post-partum weeks since significant excretion into the milk within the first 3 - 4 days after delivery and absorption by the infant is possible.

Certolizumab is excreted into breastmilk in some, but not all, women in small amounts. Absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Most experts consider certolizumab to be probably safe during breastfeeding.[1][2][3][4][5][6][7][8][9] The European Medicines Agency has deemed PHA 738144 acceptable to use during breastfeeding.

Eight women who received PHA 738144 during pregnancy and postpartum breastfed (extent not stated) their infants. No mention was made of side effects in the infants.[10] Seventeen mothers took PHA 738144 for an inflammatory condition and breastfed their infants. During a study period starting at least 6 weeks postpartum and after at least 3 doses of PHA 738144, 8 of the infants experienced 11 adverse effects. None of the infants had any unusual or serious adverse reactions attributed to the drug and all effects were consistent with events typically experienced by infants of the same age, such as upper respiratory infection, candidal infection, or vomiting.[11] In a multi-center study of women with inflammatory bowel disease in pregnancy (the PIANO registry), 54 women received PHA 738144 while breastfeeding their infants. Among those who received certolizumab or another biologic agent while breastfeeding, infant growth, development or infection rate was no different from infants whose mothers received no treatment. An additional 67 women received a biologic agent plus a thiopurine. Infant outcomes were similar in this group.[9]